Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 2
1976 1
1978 1
1981 1
1982 1
1984 2
1988 2
1991 3
1992 2
1993 2
1996 1
1997 1
1998 1
1999 1
2001 2
2003 1
2004 1
2005 1
2007 1
2010 1
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
The asterisk in your search was ignored. You must use 4 or more characters for a wildcard search. Lengthen the root word to search for all endings.
Page 1
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J. Gianni L, et al. Lancet. 2010 Jan 30;375(9712):377-84. doi: 10.1016/S0140-6736(09)61964-4. Lancet. 2010. PMID: 20113825 Clinical Trial.
METHODS: We compared 1 year of treatment with trastuzumab (given as neoadjuvant and adjuvant treatment; n=117) with no trastuzumab (118), in women with HER2-positive locally advanced or inflammatory breast cancer treated with a neoadjuvant chemotherapy …
METHODS: We compared 1 year of treatment with trastuzumab (given as neoadjuvant and adjuvant treatment; n=117) with no trastuzumab (118), in …
Intravenous or oral adjuvant CMF for node-positive breast cancer.
Lindeman GJ, Boyages J, Driessen C, Langlands AO. Lindeman GJ, et al. Aust N Z J Surg. 1992 Jul;62(7):556-62. doi: 10.1111/j.1445-2197.1992.tb07050.x. Aust N Z J Surg. 1992. PMID: 1610324
To assess the optimal duration and method of administration of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy, 116 patients with positive axillary nodes after total mastectomy and axillary dissection were reviewed retrosp …
To assess the optimal duration and method of administration of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil …
Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT, Albanell J, Aranda J, Munarriz B, Campbell J, Diaz-Rubio E; GEICAM Group (Spanish Breast Cancer Research Group), Spain. Martin M, et al. Ann Oncol. 2003 Jun;14(6):833-42. doi: 10.1093/annonc/mdg260. Ann Oncol. 2003. PMID: 12796019 Free article. Review.
BACKGROUND: The purpose of this study was to determine the relative efficacy of doxorubicin versus methotrexate in combination with intravenous cyclophosphamide and 5-fluorouracil (FAC versus CMF) as adjuvant chemotherapy for operable breast …
BACKGROUND: The purpose of this study was to determine the relative efficacy of doxorubicin versus methotrexate in combination with …
Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer.
Armstrong DK, Fetting JH, Davidson NE, Gordon GB, Huelskamp AM, Abeloff MD. Armstrong DK, et al. Breast Cancer Res Treat. 1993 Dec;28(3):277-84. doi: 10.1007/BF00666589. Breast Cancer Res Treat. 1993. PMID: 8018956 Clinical Trial.
Up to 15% of women with breast cancer have locally advanced disease at diagnosis. The poor response of these patients to local therapy alone and the frequent development of disseminated disease suggest that early intensive systemic therapy may b …
Up to 15% of women with breast cancer have locally advanced disease at diagnosis. The poor response of these pat …
Intravenous administration of cyclophosphamide, methotrexate and 5-fluorouracil in metastatic breast cancer. A pilot study.
De Lena M, Brandi M, Logroscino A, Lorusso V, Paradiso A, Maiello E. De Lena M, et al. Tumori. 1988 Feb 29;74(1):57-63. doi: 10.1177/030089168807400110. Tumori. 1988. PMID: 3162624
Sixty-two women with advanced breast cancer were admitted to a pilot study in which a modified CMF regimen was administered. Cyclophosphamide was administered i.v. at a dosage of 600 mg/m2 on the same day as fluorouracil (600 mg/m2 …
Sixty-two women with advanced breast cancer were admitted to a pilot study in which a modified CMF regimen …
Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.
Bonadonna G, Zambetti M, Moliterni A, Gianni L, Valagussa P. Bonadonna G, et al. J Clin Oncol. 2004 May 1;22(9):1614-20. doi: 10.1200/JCO.2004.07.190. J Clin Oncol. 2004. PMID: 15117983 Clinical Trial.
PURPOSE: To assess the clinical relevance of different sequences of doxorubicin (DOX) and cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients with operable breast cancer at risk of disease relapse. ...CMF give …
PURPOSE: To assess the clinical relevance of different sequences of doxorubicin (DOX) and cyclophosphamide, methotrexate …
30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study.
Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, Valagussa P. Bonadonna G, et al. BMJ. 2005 Jan 29;330(7485):217. doi: 10.1136/bmj.38314.622095.8F. Epub 2005 Jan 13. BMJ. 2005. PMID: 15649903 Free PMC article.
OBJECTIVE: To assess the long term effectiveness of adjuvant treatment with cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients with operable breast cancer at risk of relapse, on the basis of three successive randomised …
OBJECTIVE: To assess the long term effectiveness of adjuvant treatment with cyclophosphamide, methotrexate, and fluorouraci …
Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes.
Moliterni A, Bonadonna G, Valagussa P, Ferrari L, Zambetti M. Moliterni A, et al. J Clin Oncol. 1991 Jul;9(7):1124-30. doi: 10.1200/JCO.1991.9.7.1124. J Clin Oncol. 1991. PMID: 2045854 Clinical Trial.
In the attempt to improve current adjuvant results in patients with one to three positive axillary lymph nodes, in November 1981 we activated a prospective randomized study to assess the effectiveness of intravenous (IV) cyclophosphamide, methotrexate, …
In the attempt to improve current adjuvant results in patients with one to three positive axillary lymph nodes, in November 1981 we activate …
The Results of Chemotherapy with Two Variants of Intravenous CMF in Patients with Early Stage Breast Carcinoma; Does Dose Density Matter?
Salek R, Bayatmokhtari N, Homaei Shandiz F, ShahidSales S. Salek R, et al. Breast J. 2016 Nov;22(6):623-629. doi: 10.1111/tbj.12652. Epub 2016 Aug 19. Breast J. 2016. PMID: 27540897 Clinical Trial.
No direct comparisons can be made in early stages of breast cancer, between the intravenous combinations of: cyclophosphamide, methotrexate, and fluorouracil; named modified versions of CMF with the classical oral version of CMF …
No direct comparisons can be made in early stages of breast cancer, between the intravenous combinations of: cycloph …
Feasibility of concurrent adjuvant chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer.
Han S, Kim J, Sohn S, Kwak GH, Kim JY, Park K. Han S, et al. J Surg Oncol. 2007 Jan 1;95(1):45-50. doi: 10.1002/jso.20715. J Surg Oncol. 2007. PMID: 17192866
During the median follow-up period of 42 months (range: 16-60 months), 18 patients (13.5%) of the concurrent group had systemic recurrence of breast cancer, whereas 20 patients (19.1%) of the sequential group had systemic recurrence. Disease-free survi …
During the median follow-up period of 42 months (range: 16-60 months), 18 patients (13.5%) of the concurrent group had systemic recurrenc …
29 results